C4X Discovery Holdings PLC
LSE:C4XD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.8
18.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
C4X Discovery Holdings PLC
C4X Discovery Holdings PLC
PP&E Net
C4X Discovery Holdings PLC
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
PP&E Net
ÂŁ275k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
PP&E Net
ÂŁ82.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
PP&E Net
ÂŁ1.9m
|
CAGR 3-Years
100%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
PP&E Net
ÂŁ279k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
|
Ergomed PLC
LSE:ERGO
|
PP&E Net
ÂŁ5.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
PP&E Net
ÂŁ20.2m
|
CAGR 3-Years
81%
|
CAGR 5-Years
61%
|
CAGR 10-Years
79%
|
|
C4X Discovery Holdings PLC
Glance View
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).
See Also
What is C4X Discovery Holdings PLC's PP&E Net?
PP&E Net
275k
GBP
Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's PP&E Net amounts to 275k GBP.
What is C4X Discovery Holdings PLC's PP&E Net growth rate?
PP&E Net CAGR 5Y
31%
Over the last year, the PP&E Net growth was -55%. The average annual PP&E Net growth rates for C4X Discovery Holdings PLC have been -20% over the past three years , 31% over the past five years .
You don't have any saved screeners yet
